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Abstract
Technological developments in radiation therapy and other cancer therapies have led to a
progressive increase in five-year survival rates over the last few decades. Although acute effects
have been largely minimized by both technical advances and medical interventions, late effects
remain a concern. Indeed, the need to identify those individuals who will develop radiation-
induced late effects, and to develop interventions to prevent or ameliorate these late effects is a
critical area of radiobiology research. In the last two decades, preclinical studies have clearly
established that late radiation injury can be prevented/ameliorated by pharmacological therapies
aimed at modulating the cascade of events leading to the clinical expression of radiation-induced
late effects. These insights have been accompanied by significant technological advances in
imaging that are moving radiation oncology and normal tissue radiobiology from disciplines
driven by anatomy and macrostructure to ones in which important quantitative functional,
microstructural, and metabolic data can be noninvasively and serially determined. In the current
article, we review use of positron emission tomography (PET), single photon emission
tomography (SPECT), magnetic resonance (MR) imaging and MR spectroscopy to generate
pathophysiological and functional data in the central nervous system, lung, and heart that offer the
promise of, (1) identifying individuals who are at risk of developing radiation-induced late effects,
and (2) monitoring the efficacy of interventions to prevent/ameliorate them.
INTRODUCTION
Radiation therapy (RT) remains one of the major treatment options for cancer patients;
approximately 60% of all newly-diagnosed patients will receive RT sometime during the
course of their treatment (1). RT represents a targeted, noninvasive, and potentially organ-
preserving therapy. However, the total dose that safely can be administered to a tumor is
limited by the risk of both acute- and late-radiation-induced injury to those normal tissues
unavoidably included in the treatment volume. Ongoing advancements in RT and other
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cancer therapies have resulted in a progressive increase in five-year survival rates over the
last 50 years; 68% of adult and 81% of pediatric cancer patients now survive beyond five
years (2). In general, acute effects have been minimized by both technical advances and
medical interventions. However, for the ~12 million long-term survivors, there are no
proven interventions to prevent or mitigate radiation-induced late effects. Thus, the need to,
(1) identify those individuals who will develop radiation-induced late effects, and (2)
develop interventions to prevent or mitigate these radiation-induced late effects is currently
recognized as a critical area of radiobiology research (3).
Preclinical studies carried out over the last two decades clearly demonstrate that radiation-
induced late effects arise not simply from mitotic cell death of specific target cell clonogens,
but more importantly, from complex and dynamic interactions between multiple cell types
within an organ (4–7). Thus, normal cells are active participants in the response to injury
that is hypothesized to initiate an ongoing, chronic process that leads to progressive damage.
Although the exact specific pathogenic mechanisms remain to be determined, late radiation
injury can be prevented/ameliorated by pharmacological therapies focused on modulating
steps in the cascade of events leading to the clinical expression of radiation-induced late
effects (8).
These recent advances in our understanding of how radiation-induced late effects develop
and how they can be modulated have been accompanied by significant technological
advances in imaging that offer the promise of identifying individuals who are at risk for
developing radiation-induced late effects. Thus, normal tissue radiobiology is moving from a
discipline utilizing conventional histologic analysis of fixed tissues from many experimental
groups with large numbers of animals collected over many time points, to one in which
noninvasive in vivo imaging enables serial assessment of pathophysiological and functional
processes in fewer groups with smaller numbers of animals, where each animal serves as its
own control (9, 10). This process has also been facilitated by advances in clinical imaging
that have shifted radiation oncology from a discipline driven by anatomy and structure to
one in which important quantitative functional data can be determined (11, 12).
[18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging provides
functional data on normal tissue metabolic activity, while other radiotracers can image
physiologic parameters such as angiogenesis (13), hypoxia (14), cardiac function (15), and
brain function (16). Single photon emission computed tomography (SPECT) has been used
to measure perfusion (17). Magnetic resonance imaging (MRI) has become increasingly
important with its ability to assess functional metrics including regional perfusion (18), lung
ventilation (19), and brain structure, as well as function (20, 21); In addition, metabolic
states can now be assessed with MR spectroscopy (MRS) (22). More recently,
multimodality imaging with PET/CT and SPECT/CT has become commonplace in radiation
oncology, and ongoing research is investigating combining PET or SPECT with MRI (23).
In the current article, we review the use of pathophysiologic and functional imaging that
offers the promise of, (1) identifying individuals who are at risk for developing radiation-
induced late effects and (2) monitoring the efficacy of interventions to prevent or mitigate
them. Our focus will be on central nervous system (CNS), lung, and cardiac normal tissues,
and will include discussions of opportunities for future research in this field.
CNS Injury
Based on the time of clinical expression, radiation-induced brain injury is described in terms
of acute, early-delayed, and late-delayed reactions (5). Acute injury (acute radiation
encephalopathy), expressed in days to weeks after irradiation, is rare under current RT
regimens. Early delayed injury occurs from 1–6 months postirradiation and can involve
transient demyelination with somnolence, which is mainly seen in children but also can
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affect adult patients in the first 2 months after RT. While these early injuries can result in
severe reactions, they usually resolve within 1–3 months, either spontaneously or following
treatment with corticosteroids and their severity is not necessarily predictive of the more
devastating late effects. Late delayed effects, characterized histopathologically by
demyelination, vascular abnormalities and, ultimately, white matter necrosis (24), are
observed > 6 months postirradiation after relatively high doses (>60 Gy) of fractionated RT
(5, 25).
There is a growing awareness of intellectual deterioration in patients receiving brain
irradiation (26) that can occur with relatively low total doses and in the absence of apparent
structural lesions. Although diverse in character, this often includes hippocampal-dependent
functions including learning, memory, and spatial information processing. Cognitive
impairment, including dementia, induced by partial- or whole-brain irradiation (WBI) is
reported to occur in up to 50% of adult patients who are long-term (>6 months
postirradiation) survivors (27–29). The resultant impact on quality of life (QOL) has become
an extremely important concern for long-term survivors, particularly for the adult survivors
of childhood cancer who present with an extraordinarily high incidence of late, and often
permanent, complications, including cognitive sequelae, arising from combined RT and
chemotherapy (30–33).
Currently there are no validated diagnostic procedures for determining who will or will not
develop radiation-induced brain injury, including cognitive impairment, or who will/will not
respond favorably to therapies aimed at preventing or ameliorating these deficits. Radiation-
induced late effects occur within the closed cranial cavity, and thus, noninvasive techniques
offer the opportunity to study this significant side effect of brain tumor RT. Early studies
used CT, histology and neurological changes to investigate radiation-induced late effects in
the dog brain after hemibrain irradiation with large single doses (34). MRI use in the clinic
has been translated into experimental studies of the effects of large single doses on the rat
(35–37), cat (38, 39), dog (40, 41), and pig (42) brain as well as fractionated irradiation of
the mouse brain (43). CT and MRI have enabled serial evaluation of animals over a
prolonged period and identified radiation-induced brain injury as either a white matter
hypodensity on CT or an increased T2 signal abnormality on MRI.
A limitation of these studies is that the primary morbidity associated with modern brain RT
techniques is functional, rather than structural. For brain tumor patients, radiation-induced
cognitive impairment represents a major morbidity than can markedly impact their QOL.
Progressive cognitive impairment can occur without any MRI evidence of white matter
necrosis (44). Similarly, fractionated (f)WBI of the rat brain leads to progressive cognitive
impairment in the absence of demyelination, gliosis, and white matter necrosis (45).
Cognitive impairment can also occur with no change in the number of oligodendrocytes and
myelinated axons, or thickness of myelin sheaths 1 year following fWBI (46). These
findings suggest that more sensitive imaging techniques that focus on microstructure [e.g.,
diffusion tensor imaging (DTI) (21) and metabolic changes (MRS) (22)] might detect the
neurobiological changes that lead to altered neural processing following fWBI.
MRI
MRI utilizes magnetic fields to generate tissue images by exciting protons and monitoring
them as they relax. In addition to standard structural images that look at gross anatomy, DTI
is capable of assessing tissue microstructure by measuring the diffusion or motion of water
molecules along multiple tensors within each image voxel. DTI provides a mechanism to
identify microstructural abnormalities due to radiation injury well before macrostructural
changes are visible (47, 48). A minimum of six tensors need to be acquired for calculating
the DTI indexes. Water diffusion along each tensor is measured for each voxel and by
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averaging the diffusion in all directions, the mean diffusivity, or trace, is calculated. Areas
with little structure allow water to freely diffuse and will have higher mean diffusivity
values than areas with more structure, such as the white matter. The Fractional Anisotropy
(FA) is determined from calculating the first, second and third eigenvalues (λ1, λ2 and λ3)
of the tensor field, which describes whether diffusion is either elliptical or spherical. When
the voxel is placed within highly-structured regions such as white matter bundles, water
diffusion is restricted or anisotropic, and FA is near 1 (Fig. 1A, aqua arrow head within the
anterior commissure). High FA values indicate that λ1 is significantly greater than the
perpendicular eigenvalues λ2 and λ3, which creates an elliptical or tube-shaped diffusion
pattern. When the voxel is placed in less structured regions, such as the cerebral spinal fluid
(Fig. 1A, yellow arrow head), or demyelinated white matter, water diffusion is less restricted
or isotropic, and FA is closer to 0. Lower FA values indicate a smaller difference between
λ1 and the perpendicular eigenvalues λ2 and λ3, which creates a more spherical diffusion
pattern.
Parallel diffusivity (λ∥) refers to the first eigenvalue and represents the greatest amount of
diffusion in one direction, which is typically along the axons of white matter tracts. DTI
processing frequently color-codes the directions of diffusion to allow greater separation of
different anatomical tracts and interpretation of the direction of information flow (Fig. 1B);
therefore it actually shows the movement of water in 3-dimensional (3D) space.
Perpendicular diffusivity (λ⊥) refers to diffusion along the second and third eigenvalues (λ2
and λ3) and is commonly calculated as an average between them. The second eigenvalue is
the second highest value of diffusion perpendicular to λ1, while λ3 is restricted to diffusion
perpendicular to both λ1 and λ2. Quantitative measures obtained from these DTI indices
have been interpreted to distinguish between myelin loss and axonal injury. With
demyelination, there is a greater increase in perpendicular diffusivity (λ⊥) with little or no
change in parallel diffusivity (λ∥), while with axonal injury there is a decrease in λ∥ with
little or no change in λ⊥ (49, 50). While, these interpretations are limited to white matter
tracts; differences in DTI parameters are also found in cortical areas and represent
alterations in how water diffuses through the extracellular matrix, synaptic field, and/or
small myelinated/unmyelinated axons. These DTI indices can be compared on a voxel-by-
voxel basis throughout the 3D brain space, or on a region-of-interest (ROI) basis within
specific anatomical regions (Fig. 1C).
DTI as an Imaging Biomarker of Late CNS Toxicity
DTI has been used to assess early white matter injury in both pediatric and adult patients
treated with partial- and WBI (51–55). A recent, prospective DTI study was undertaken at
the University of Michigan in which patients with high-grade gliomas (n = 19), low-grade
gliomas (n = 3), and benign tumors (n = 3) received partial brain irradiation; DTI was
performed before, during, and after irradiation (51). Analyses revealed progressive changes
secondary to RT in the genu (anterior portion) and splenium (posterior portion) of the corpus
callosum. During the first 3 months post-RT, dose-dependent demyelination (i.e., increased
λ⊥ > λ∥) was noted predominantly in regions receiving high doses of RT. However, 6
months following the start of RT, the diffuse demyelination was no longer limited to the
high RT dose regions. The latency in diffuse demyelination suggests an opportunity for
early intervention to avoid permanent late radiation-induced white matter damage (51). This
study confirms that DTI indices have the potential to detect changes in the normal appearing
white matter (NAWM) of CNS patients receiving partial brain irradiation.
Similar preclinical data are available for example, DTI of the rat brain 1 year after right
hemibrain irradiation with 28 Gy of 6 MV photons revealed a significantly greater decrease
in functional ainisotropy (FA) in the ipsilateral fimbria of the hippocampus than in the
external capsule, indicating selective vulnerability of the fimbria to irradiation (48).
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Longitudinal evaluation of white matter injury in the rat brain imaged 2 to 48 weeks after 25
and 30 Gy hemibrain irradiation revealed a progressive reduction in FA, which was driven
by a reduction in λ∥ from 4 to 40 weeks postirradiation, and an increase in λ⊥ with a return
to baseline for λ∥ at 48 weeks postirradiation (56). Moreover, changes in λ∥ correlated with
reactive gliosis, while λ⊥ correlated with demyelination. In middle-aged rats treated with
fWBI, DTI performed 1 year postirradiation revealed no apparent changes in FA in heavily-
myelinated axons (corpus callosum, cingulum, and deep cortical white matter). However,
significant fWBI-induced injury was present in the superficial parietal cortex as indicated by
a fWBI-induced decline in FA in the more anterior slices through the parietal cortex (57).
These findings suggest that fWBI-induced changes may be more pronounced in the less
myelinated/unmyelinated axons, extracellular matrix, or synaptic fields rather than in
heavily-myelinated tracts.
Pediatric studies also support the utility of DTI as a clinically-relevant tool for the
assessment of treatment-related neurotoxicity, and as a potential adjunct to intelligence
quotient (IQ) scores. A cross-sectional DTI study of post-treatment survivors of childhood
medulloblastoma and acute lymphoblastic leukemia (ALL) was performed and compared to
age-matched controls. Decreases in FA were associated with declines in IQ scores after
adjusting for the effects of age, RT dose, and time interval from treatment (52). Significant
decreases in FA were noted in the white matter of both frontal and parietal lobes in
childhood medulloblastoma survivors compared to controls. Greater declines in FA were
noted in frontal compared to parietal lobes for the same RT dose, suggesting increased
radiosensitivity of the frontal lobes which are myelinated and develop throughout childhood
and adolescence (53). Additionally, late structural abnormalities in normal appearing
cerebral white matter were indicated by significantly-reduced FA values in the temporal
lobe, hippocampus, and thalamus of adult survivors treated for ALL following WBI
compared to age-matched controls (54). Although changes in structural properties of
NAWM are noted postirradiation, prospective neurocognitive testing prior to RT is required
to correlate these findings with late-delayed radiation-induced cognitive impairment.
Radiation-induced injury to the hippocampus region may be associated with long-term
deficits in learning, memory, and executive function. Demyelination or axonal injury within
this area could impact the efficiency of communication between the hippocampus and the
rest of the cortex, thereby impacting learning and memory. In a preliminary study at the
University of Michigan, 12 patients with brain metastases treated with fWBI with RT total
doses of 30–37.5 Gy were prospectively assessed with DTI prior to RT, at the end of RT,
and one month following RT. Specific ROIs included the parahippocampal cingulum, a
prominent white matter fiber tract bundle of the limbic system. A decrease in FA was noted
in the parahippocampal cingulum 1 month after completion of fWBI (Fig. 2) (58). More
specifically, a significant increase in λ⊥ without a significant change in λ∥ was noted in this
region, suggesting early demyelination of the white matter (Fig. 2D). These results suggest
that DTI indices may be a useful noninvasive biomarker to, (1) monitor patients who are
treated with hippocampal-sparing WBI regimens, and (2) for predicting cognitive
performance following RT (59).
In summary, DTI is able to detect early changes in white matter integrity. These changes in
the properties of NAWM may be related to late-delayed cognitive decline. Currently, on-
going studies combining DTI and neurocognitive testing are investigating longer follow-up
times (up to 18 months after RT) to determine the predictive power of these MRI
biomarkers. By identifying patients with early changes in white matter integrity, it may be
possible to predict which patients will have greater inherent radiation sensitivity, so that
interventions can begin earlier.
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Vascular damage may also play a critical role in the development of late radiation-induced
injury, including radiation necrosis (60, 61). Early histopathologic changes noted in blood
vessels following irradiation include vessel dilatation, endothelial cell enlargement, and
perivascular astrocyte hypertrophy, which can lead to blood-brain barrier (BBB) disruption,
increased permeability, and edema. Acute vascular injury following irradiation potentially
can be detected prior to the development of acute demyelination and white matter necrosis
(62, 63). Dynamic contrast enhanced (DCE) MRI using T1-weighted imaging allows
quantitative assessment of vascular permeability by repeatedly imaging brain tissue prior to
and following a short bolus injection of an MRI tracer into the blood stream. By tracking the
movement of the tracer into the image volume and using compartmental modeling, a transfer
constant or Ktrans value for passive leakage of the tracer from the intravascular space to the
extravascular space can be calculated (64). Areas with high Ktrans values have a leaky
vascular wall that allows movement of the tracer out of intravascular space more readily
than from areas with intact vasculature. These functional characteristics of the vascular
microenvironment may provide an early indication of radiation-induced changes that
correlate with late cognitive impairment.
In a preliminary clinical study, changes in blood plasma volume (Vp) and Ktrans were
evaluated in normal-appearing cerebral tissue following partial brain irradiation (65). Ktrans
was highest during the 6th week of RT and decreased in a dose-dependent manner following
the conclusion of therapy; it returned to baseline levels 6 months postirradiation. Increases
in Ktrans indicate changes in BBB permeability/perfusion effects which could be related to
radiation-induced cell death and apoptosis(63). Vp however, displayed a dose-dependent
response with low fractionated regimens (<20 Gy) showing no significant increase in Vp.
Higher-dose regimens showed a differential increase in Vp during RT with larger doses
inducing faster and larger increases. Although Vp decreased after RT; this decrease was still
less than baseline levels 6 months postirradiation. At 6 months postirradiation, vascular
microenvironment changes evident during the 3rd week of RT within left hemisphere frontal
and temporal lobes were significantly correlated with declines in verbal learning scores on
the Hopkins Verbal Learning Test (HVLT). When the temporal lobe was divided into
hippocampal and nonhippocampal ROIs in 12 patients, Vp at 3 weeks continued to correlate
with the HVLT learning scores 6 months postirradiation for both ROIs (65). Validation
studies of these initial findings are currently on-going. However, they suggest that sparing of
the hippocampus alone may not be sufficient to protect memory function following WBI.
MR Proton Spectroscopy
Proton MRS is a noninvasive technique to, (1) interrogate metabolic distributions in the
brain (66, 67), (2) differentiate radiation necrosis from brain tumor progression (68, 69), and
(3) serve as an indicator of neurotoxicity following experimental (48, 70) and clinical brain
irradiation (71–76). Metabolites detected in brain tissue include choline-containing
compounds, creatine, glutamate, lactate, N-acetylaspartate (NAA), myoinositol (mI) and
taurine. The concentration of each of these metabolites can be mapped from 2D or 3D
spectroscopic images having a voxel size of 0.7–1 cm3. The metabolite, N-acetylaspartate
(NAA) is predominantly a neuronal marker, and decreases are associated with neuronal
damage and dysfunction secondary to radiation. Choline is associated with cell membrane
synthesis and/or increased metabolic turnover; it is elevated in both tumors and
inflammatory processes. Creatine is a marker of energy metabolism with relatively constant
concentrations throughout the brain (77), while mI is a glial cell marker and has been used
as an indicator of myelin breakdown (78).
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Very little preclinical data are available on MRS detection of metabolite changes in the
normal brain following irradiation. Using a 4.7T MR spectrometer and a voxel size of
approximately 30 mm3, Herynek et al. (70) observed decreases in creatine and NAA 8 and
12 months after bilateral Gamma Knife irradiation of the hippocampus of young adult male
rats with 35 Gy, a dose that led to severe functional and structural impairment. Chan et al.
(48) used a 7T MR spectrometer and a voxel size of 64 mm3 to determine significant
increases in choline, glutamate, lactate, and taurine levels 12 months after right hemibrain
irradiation of young adult male rats with a single dose of 28 Gy of 6 MV photons. These
changes in white matter were confirmed histologically. Using a similar 7T spectrometer and
a larger voxel size of 125 mm3 (Fig. 3), Atwood et al. (79) reported a potential relationship
between radiation-induced changes in rat brain metabolites and cognitive impairment 52
weeks after fWBI. MRS spectra obtained 12 weeks after 40 Gy fWBI failed to show any
significant differences in brain metabolites or cognitive impairment between the fWBI and
sham-irradiated rats. In contrast, analysis of MR spectra obtained 52 weeks postirradiation
revealed significant increases in the NAA/total creatine + phosphocreatine (tCr) and the
glutamate + glutamine/tCr ratios, as well as a decrease in the mI/tCr ratio compared with
age-matched sham-irradiated controls. Assessment of cognitive function in these rats 54
weeks postirradiation revealed a significant reduction in the irradiated animals. Thus, these
findings suggested that MRS may be a sensitive tool to detect changes in radiation-induced
brain metabolites that may be associated with radiation-induced cognitive impairment (79).
However, more recent studies using this fWBI model indicated that these changes in rat
brain metabolites occur after the expression of radiation-induced cognitive impairment, and
do not appear to cause or predict the onset of radiation-induced cognitive impairment (45).
MRS has also been used to assess metabolite changes in NAWM following RT (71–75). In a
cross-sectional study of ALL survivors following intrathecal methotrexate and prophylactic
cranial irradiation, MRS detected decreasing NAA/Cr and Cho/Cr ratios with increasing
time after RT ranging from 5.6 to 19 years, suggesting long-term brain injury secondary to
decreases in NAA and Cho (76).
In an initial prospective study of 11 adult patients with low-grade gliomas or benign tumors,
such as pituitary adenomas and meningiomas treated with partial brain irradiation, MRS
demonstrated significant alterations in brain metabolites in normal appearing brain
parenchyma, both during irradiation and over a 6-month period post-RT. Similar to the
previous study, decreases were also noted in both the NAA/Cr and Cho/Cr ratios starting 3
weeks following RT that persisted for up to 6 months (71).
Several small studies have demonstrated significant alterations in brain metabolites in
normal appearing brain parenchyma following RT (72–75). Transient metabolic changes
were noted in glioma patients 4 months following RT with increases in the Cho/NAA and
Cr/NAA ratios that appeared to resolve over time (72). In a prospective study of high-grade
glioma patients, similar findings were noted in normal appearing brain parenchyma
following RT. Transient increases in the Cho/NAA ratios were noted 2 months following
RT in NAWM regions receiving low, moderate, and high RT doses; recovery was dose-
dependent (73). Similarly, in a cross-sectional adult glioma study, metabolite changes were
much more pronounced in radiation-induced hyperintensity areas (RIHA) compared to
NAWM. In RIHA regions, a decrease in both NAA and Cho was suggestive of myelin
damage and axonal necrosis; in NAWM regions, a decrease in Cho was suggestive of
membrane damage in myelin-producing oligodendrocytes that accompanies impaired tissue
perfusion due to endothelial radiation effects (74).
In summary, MRS is a noninvasive imaging technique that can monitor radiation-induced
changes in brain metabolites. Clinically, there are significant technical challenges that
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remain in reproducibly measuring chemical metabolites near brain tumor regions. There
may be signal contamination from the ROI’s proximity to the ventricles, scalp and surgical
clips. Normal tissues adjacent to the tumor bed may also affect local-field homogeneity and
data quality (77). Ongoing studies involve the temporal dynamics of radiation-induced
injury and its associated metabolite changes as well as the relationship between the detection
of early tissue damage and the development of late symptomatic cognitive impairment.
PET
The effect of fWBI on brain function has recently been investigated in nonhuman primates
(NHPs) using FDG-PET imaging by determining local rates of glucose metabolism/uptake
(CMRglc) during a Delayed-Match-to-Sample (DMS) cognitive function task (80). The
CMRglc in a brain region is an indicator of neurosynaptic activity in that region, and has
become a standard technique in dementia research (81). PET scans performed 1 week prior
to fWBI revealed that the brain regions activated during the DMS task were the dorsal
prefrontal cortex (DPFC), the medial temporal lobe (MTL), the parietal cortex (precuneus),
and dorsal striatum (DStr); areas repeatedly implicated in human and NHP cognitive
function (82, 83). As anticipated, PET scans performed 9 months after fWBI, when
cognitive function was significantly impaired, revealed reduced glucose metabolism in the
cuneate and DPFC regions compared to pre-fWBI values (80). In contrast, glucose
metabolism in the cerebellum and thalamus, regions that were not engaged during the DMS
task prior to fWBI, was increased, indicating a potential imbalance in frontal subcortical
circuits (Fig. 4) (84). Indeed, decreased capacity to perform higher-order executive functions
has been shown to involve the DFPC, hippocampus, cuneate, and motor areas in cancer
survivors following fWBI (44).
Lung Injury
Symptomatic pulmonary injury is one of the most common side effects in patients
undergoing thoracic RT (85). Noninvasive radiologic imaging techniques can be used to
assess regional damage, reduced function, and potentially to predict clinically-relevant
outcomes. However, radiologic evidence of pulmonary injury is not always accompanied by
clinical symptoms. For example, in lung cancer patients who receive RT, 50% to 100% will
develop radiologic evidence of lung injury, while only 5% to 35% develop clinical
symptoms (85–87). Similarly, for breast cancer patients who receive RT, up to 63% develop
radiologic evidence of lung injury, while 34% or fewer develop clinical symptoms (88–93).
The likelihood of clinical pulmonary injury is related to RT dose, irradiated volume, and
fractionation schedule. Systemic therapies (e.g., chemotherapy, hormone therapy, or
immunotherapy) may affect the incidence and severity of RT-induced injuries, as may
patient-specific factors, such as pre-treatment pulmonary function and a history of smoking
(86, 94–98).
Pulmonary injuries are typically divided into early- (or acute)-phase injuries and late- phase
injuries. Radiation pneumonitis, an early-phase complication usually developing within 6
months of RT, is commonly characterized by cough and dyspnea, and typically responds
well to steroids. It occasionally resolves without treatment (92, 99, 100). Fibrotic injury is a
late complication, usually presenting at least 6 months post-RT and, if symptomatic, can
involve progressive dyspnea and possible mortality (86, 97).
Radiologic evidence of radiation pneumonitis can be variable in appearance with increased
density associated with inflammation (acute) (101), or increased density accompanied by
contraction, and pleural thickening (late) (102). The frequency of detecting radiologic
abnormalities depends on the sensitivity of the radiographic assessment. For example,
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computed tomography (CT) is more sensitive than chest radiography because it provides 3D
visualization of the lung (102).
CT and SPECT
Preclinical studies using mouse and rat models have demonstrated that serial CT imaging
can be used to demonstrate both dose-dependent increases in lung density following single-
dose irradiation (103, 104), and strain-specific differences in acute- and/or late-radiation
injury (105). More recently, a methodology for quantitatively measuring structural regional
changes in homogeneously-irradiated rat lungs has been developed (106). Lung function has
been assessed using radionuclide perfusion assays. And, it was shown that hemithoracic
irradiation of the rat lung leads to decreased arterial perfusion as assessed using
technecium-99m-labeled macroaggregated albumin that is evident within 4 to 6 weeks of
irradiation with a single dose of 25 (107) or 28 Gy (108).
Noninvasive imaging techniques for assessing RT-induced lung injury have been previously
described in detail (94, 102). CT scans provide lung tissue density information that can be
associated with 3D RT dose-distribution maps. SPECT imaging is a sensitive means of
assessing regional lung function such as perfusion and ventilation. RT affects both
ventilation and perfusion, which is best demonstrated by the work of researchers at the
Netherlands Cancer Institute (NKI; 109). Their data, and that of several others, suggest that
perfusion is a more sensitive measure of normal tissue injury than is ventilation.
Physiologically, the lung is better able to reduce blood flow to unventilated areas (via
capillary/vascular constriction) than to reduce ventilation to unperfused areas (bronchi are
less able to be constricted). Therefore, reductions in ventilation will generally also cause
perfusion reductions, but the reverse is less-often true. Thus, perfusion is a more sensitive
metric for assessing RT-induced lung injury.
For both CT and SPECT, pre- and post-RT images can be compared to the 3D dose
distribution to study the dose-dependent nature of RT-induced regional lung injury.
Perfusion defects are more common than ventilation defects, and both are more common
than changes in CT (94). Investigators from Duke University, the NKI, and the Princess
Margaret Hospital (PMH) have reported prospective data relating lung RT dose to CT-
defined lung injury (100, 109, 110). In a study of 25 patients irradiated for malignant
lymphoma, Boersma et al. at the NKI observed dose-dependent increases in CT density 3 to
4 months post-RT (109). Mah et al. at the PMH studied changes in CT density up to 6
months following lung irradiation for 54 patients; dose-dependent increases in the frequency
of CT-defined lung injury were observed (110). At Duke, Levinson et al. studied changes in
local CT density for 13 patients with lung cancer (100). Significant increases in CT density
were observed for regions of lung receiving >60 Gy; smaller increases were observed for
regions receiving smaller doses. The pre- and post-RT CT images, for a typical irradiated
lung cancer patient, are shown in Fig. 5A and B. Increased density is seen on the post-RT
CT image (indicated by an arrow in Fig. 5B) and is associated with inflammation.
Similar to CT images, pre- and post-RT SPECT images can be compared to the 3D dose
distribution to study the dose-dependent nature of regional RT-induced lung injury. Pre- and
post-RT SPECT perfusion images, including the isodose distributions, for an irradiated lung
cancer patient are shown in Fig. 6A and B; the dose-response curve for RT-induced
reductions in regional perfusion are shown in Fig. 6C. Using 3D image-fusion techniques,
investigators at Duke and NKI have related changes in pre- and post-RT CT density, SPECT
ventilation, and SPECT perfusion to the 3D regional dose distribution (Fig. 7) (100, 109,
111–114).
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Several investigators have established a connection between the extent of radiologic
evidence of pulmonary injury and clinically-relevant symptoms (110, 115, 116). Fan et al. at
Duke, and Theuws et al. at NKI, showed a correlation between reductions in pulmonary
function tests (PFTs) and integrated changes in regional perfusion, i.e., the integrated
response (116–118). Although statistically significant, the relatively weak correlation
between reduced PFT performance and integrated response suggests the existence of
additional factors to explain post-RT changes in PFT. A stronger association between
pulmonary symptoms (Grade ≥2) and the estimated sum of regional functional changes has
been shown by Gopal et al. (119).
Recent reports have focused on radiation-induced lung injury after stereotactic radiosurgery.
In a study of 31 patients receiving stereotactic radiosurgery for primary or metastatic lung
lesions, Aoki et al. noted asymptomatic increases in CT density 2 to 6 months post-RT, and
later fibrotic reactions at 6 and 15 months post-RT (120). While all 31 patients developed
radiographic changes, no patients developed severe symptoms (e.g., Grade ≥2 or requiring
steroids). When follow-up CTs were compared to the dose distribution on the treatment
planning CT, investigators observed that the minimal dose for the development of CT-
defined changes in lung tissue density ranged from 16 to 36 Gy.
MRI
Contrast-enhanced MRI may also be used to describe perfusion characteristics of various
phases of RT-induced lung injury. Japanese studies suggest that MRI can also detect
radiation-induced lung injury in animal models. Shioya et al. used MR techniques to
determine the extent of radiation-induced lung tissue damage in rats within 2 weeks of a 20
Gy single fraction to the hemithorax. They found that MRI was more sensitive than
conventional imaging techniques for detecting early effects on normal tissue (121).
Ogaswara et al. also suggested that contrast-enhanced perfusion MRI may be helpful in
differentiating acute pneumonitis from late fibrosis in dogs (122).
Similar results using contrast-enhanced perfusion MRI for distinguishing acute pneumonitis
from late fibrosis have been reported in the clinical setting (122, 123). A recent study by
Muryama et al. suggested that pulmonary hypertension, detected by velocity-encoded cine
(VEC) MRI, may be used as a predictor of radiation pneumonitis (124). MRI has also been
suggested to be potentially useful to detect differences in tumor response during treatment,
with the potential to guide adaptive changes in treatment plans (123).
PET
FDG-PET imaging provides regional functional information that has potential for assessing
RT-induced lung injury. A recent study by Hart et al. at MD Anderson Cancer Center, noted
dose-dependent increases in regional FDG-PET activity in 101 esophageal cancer patients
assessed 3 to 12 weeks post-RT (125). Further, the severity of the regional inflammatory
changes appeared to be significantly correlated with the probability of symptoms. Data from
several studies using SPECT, CT, MRI, and PET to detect changes in the lung following
thoracic RT are summarized in Table 1. In some of the studies, the rate of symptomatic
shortness of breath is also noted. These data are included in the table and illustrate that
imaging is more sensitive than clinical symptoms as a marker of RT-induced lung injury.
In summary, several investigators have used a variety of imaging tools to study RT-induced
regional injury/changes. For some, there is a reasonable dose-response relationship. The
association between the extent/severity of regional imaging changes and changes in global
function is less well-defined. Additional work is needed to better clarify the relationship
between changes in regional imaging and changes in global function.
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RT to the thorax may induce both early and late cardiac effects if portions of the heart are
included in the radiation field. Patients with breast cancer and Hodgkin’s disease are
particularly at risk for developing late myocardial damage, due to their longevity and
possibly to the frequent use of anthracycline-containing chemotherapy. In general, one has
to wait at least 10 years post-treatment to see these effects manifest clinically (131). The use
of radiologic methods may allow for the early detection of treatment-associated dysfunction.
The vast majority of the available data on RT-induced heart injury use SPECT myocardial
perfusion imaging in breast cancer and Hodgkin’s disease patients. Recent studies have also
investigated the incidence of the cardiac effects of RT in lung and esophageal cancer
patients. Finally, preliminary data are available on newer imaging technologies, such as
cardiac MRI and PET, for assessing RT-induced cardiac injury in patients with thoracic
cancers. However, to our knowledge, there are no published reports using imaging
techniques to noninvasively assess radiation-induced cardiotoxicity in preclinical models.
Nevertheless, this is likely to become a fruitful area of research in the near future.
Scintigraphy and SPECT
Nuclear medicine imaging provides both qualitative and quantitative information about
regional and global cardiac function (132), and has been suggested to be a sensitive means
to assess myocardial injury in patients with coronary artery disease (133). Cardiac SPECT
techniques that produce 3D images are currently applied more frequently than are planar
scintigraphic techniques; they provide a noninvasive assessment of left ventricular
myocardial perfusion and function, such as changes in wall motion and left ventricular
ejection fraction. Scans taken in the early years following RT may be useful for estimating
subclinical damage. The incidence of perfusion defects appears to be related to the irradiated
volume of the left ventricle and largely persists for up to 6 years after RT in breast cancer
patients (134, 135).
Gyenes et al. conducted a prospective study and performed Tc-99m Sestamibi scintigraphy
prior to and ~1 year after left breast/chest wall RT in 12 patients. Six of the 12 patients
(50%) with some portion of the left ventricle within the radiation field exhibited a new
perfusion defect. Again, the location of the defects corresponded with the irradiated volume
of the left ventricle. Interestingly, neither electrocardiographic (ECG) changes nor left
ventricular segmental wall motion abnormalities were detected by echocardiography (136).
Seddon et al. performed SPECT myocardial perfusion imaging in 24 patients with left breast
tumors, and 12 control patients with right breast tumors, who had undergone RT at least 5
years previously. Myocardial perfusion defects were found in 17/24 (70.8%) of left breast
patients compared to 2/12 (16.7%) of right breast patients. Almost all myocardial defects in
left breast patients were located in the cardiac apex, the portion of heart that is incidentally
included within the RT fields (137). In a prospective study at Duke, new RT-associated
perfusion defects were detected in 16/55 (29%) of breast cancer patients 6–12 months post-
RT (Fig. 8). The incidence of perfusion deficits was related to the irradiated volume of the
left ventricle, with new defects occurring in approximately 10–20% and 50–60% of patients
with <5% and >5% of their left ventricle included within the RT fields, respectively (134).
These studies used SPECT images generated without attenuation correction. However, the
same technique was used to generate the pre- and post-RT images, and these images were
compared to each other. All of the data presented are based on comparisons of pre- vs. post-
RT images. Thus, the lack of attenuation correction does not explain these findings. For
patients who do not experience significant anatomic changes between pre- and post-RT
images, attenuation correction does not influence the validity of the results. The accuracy of
these studies is dependent on the assumption that there are not meaningful changes in the
patient’s anatomy in between the pre- and post-RT scans.
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Perfusion defects have been associated with episodes of chest pain and wall motion
abnormalities, but their clinical implications are not well understood (134, 135, 137, 138).
Further, relatively large perfusion defects appear to cause reductions in the ejection fraction
(130), although the data on this point are limited. Abnormalities detected by SPECT have
been suggested to be due to attenuation artifacts related to RT-induced pericardial scarring
of the breast or chest wall. These artifacts may be misinterpreted as defects in the anterior
myocardium (134); however, recent analyses suggest that this is unlikely (139) and that the
perfusion changes seen post-RT are “real.” Data from several studies relating SPECT
changes in the heart of breast cancer and Hodgkin’s disease patients, and preliminary data
from studies in esophageal and lung cancer patients are shown in Table 2.
MRI
MRI allows the determination of myocardial wall thickness and, with delayed hyper-
enhancement, direct visualization of myocardial injury or fibrosis; it is more sensitive than
SPECT in assessing sub-endocardial injury. Both MRI and SPECT provide information
regarding wall motion and ejection fraction, but MRI has better spatial resolution and thus
may be more accurate (153, 154). Presently, quantification of myocardial perfusion is better
developed with SPECT than with MRI (154).
While MRI provides the ability to globally assess the heart, at this time MRI has only been
used to study RT-induced cardiac disease for a small number of lung cancer patients. In pilot
studies from MD Anderson Cancer Center and Duke University, no apparent cardiac MRI
changes have been observed in a small number of evaluable patients (151, 152).
PET
There is increased interest in the use of PET to provide a map of regional myocardial
perfusion because of its improved resolution and accuracy when compared to SPECT. PET
has an advantage of possibly shorter exam times than SPECT, but is similarly limited to
imaging only the left ventricle (155). A recent case report noted increased FDG uptake
within cardiac regions receiving ≥25 Gy ~ 4 years earlier; the patient was asymptomatic and
had a normal ECG (156).
In summary, imaging has been used to define RT-induced changes in regional perfusion and
function in the left ventricle, largely relying on SPECT. Some newer imaging methods may
be better able to study RT-induced changes in imaging and function throughout the entire
heart. This is critical to better understand the cardiac effects of RT given the multiple
cardiac sub-regions and their functional interrelationship/dependency.
SUMMARY
Technological advances in biomedical imaging have enabled preclinical and clinical studies
of radiation-induced normal tissue injury to move from assessing simply anatomical changes
to generating functional, microstructural, and metabolic data. Moreover, noninvasive
approaches allow the longitudinal determination of the extent and severity of radiation-
induced normal tissue injury on an individual basis. Molecular imaging, including MR,
SPECT, and PET, holds the promise of identifying the specific targets and biological
processes that precede or underlie anatomical and functional changes (157). Recent studies
demonstrating, (1) the ability to monitor disease progression and therapy response in
neurodegenerative disorders by imaging of peripheral benzodiazepine receptors with PET
(158), (2) SPECT imaging of serotonin and dopamine receptors (159), (3) PET and MR
imaging of neuroinflammation (160–162), and (4) cardiovascular disease with MR, SPECT,
and fluorescent-tagged molecules (163), suggest that applying these techniques to radiation
biology/oncology will greatly advance our understanding of the molecular mechanisms
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underlying the development and progression of radiation-induced normal tissue injury.
These mechanistic insights will enable radiation oncologists to plan RT regimens more
rationally to minimize treatment-related morbidities, as well as intervene to improve the
outcome and QOL of their patients.
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Coronal brain slices of a male Fischer 344 × Brown Norway rat. Panel A: Fractional
Anisotropy (FA) indicates the directional water diffusion within a voxel. Fractional
anisotropy values approaching 1 (aqua arrowhead) have high directional flow and can be
seen within white matter tracts throughout the rat brain. Panel B: Fractional anisotropy can
be colored to represent the direction of flow throughout the 3D image. In this example, blue
defines flow between anterior (A) and posterior (P), red defines flow between left (L) and
right (R), and green defines flow between superior (S) and inferior (I). Colors in between
these axes represent the entire color spectrum applied in 360°. Panel C: To compare voxel-
wise and region of interest (ROI) analysis, a medial region of the lower panel from part B
has been magnified. Voxel analysis will compare across individuals the area of tissue that is
contained within each voxel and relies on voxels being in the same region across all
subjects. As can be seen, structures are split across voxels creating partial volumes, which
contain two or more tissue types or anatomical regions. ROI analysis relies on an individual
or automated segmentation to delineate particular structures such as the cingulum bundles
(a) or corpus callosum (b). Both methods have limitations and benefits, and should be used
with a clear understanding of the assumptions of the methodology whether alone or in
combination.
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Prospective human MR DTI study to assess changes in normal appearing white matter
following whole-brain radiation therapy (WBRT). Panel A shows an MR T1–weighted axial
slice illustrating the different regions of interest defined for each patient including
parahippocampal cingulum outlined in green (right hemisphere) and light blue (left
hemisphere). Temporal lobe white matter (yellow and blue) regions are also shown. Panel B
shows an MRI T1-weighted MR axial slice obtained at baseline prior to WBRT; the
parahippocampal cingulum is outlined in white. In panel C, a calculated MR DTI map of λ⊥
is shown. Parahippocampal white matter prior to WBRT appears dark on λ⊥ images
indicating greater diffusion in the direction parallel to the white matter fiber tracts. However,
1 month following 30 Gy WBRT, there is a significant increase in λ⊥ indicating early
demyelination in the region of the parahippocampal cingulum (panel D).
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High-resolution T2-weighted control (panel a) and axial (panel b) images illustrating the
location of the 5 × 5 × 5 mm voxel used to obtain the MR spectra in the fWBI rat brain (79).
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[18F]FDG-PET scans of cerebral glucose metabolism 9 months after fWBI. Upper panel:
post-irradiation < pre-irradiation. Blue areas in the cuneate cortex and prefrontal cortex
exhibited less metabolic activity in fWBI scans obtained 9 months after fWBI than in the
scans prior to fWBI. Lower panel: post-irradiation > pre-irradiation: The red areas in the
cerebellum and thalamus showed greater metabolic activity in the fWBI scans obtained 9
months after fWBI than in the scans prior to fWBI. The color bar is the degree of intensity
difference shown as a scale of t values with P < 0.001 (80).
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Shows the (panel A) pre- and (panel B) 12-month post-radiation therapy (RT) computed
tomography images from an irradiated lung cancer patient. The beam paths are shown
(anterior, posterior, oblique). The arrow indicates the region of increased CT density in the
irradiated medial left lung following RT. [Adapted from Kocak (102) with permission.]
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Shows the (panel A) pre- and (panel B) 6-month post-radiation therapy (RT) transverse
SPECT perfusion images from an irradiated lung cancer patient. The RT dose distribution,
relative to isodose contours, is also shown. Panel C shows the dose-response curve for RT-
induced reductions in regional perfusion from the patient’s SPECT scans; post-RT perfusion
defects are seen most predominantly within regions of the lung receiving >60 Gy. [Adapted
from Kocak (102) with permission.]
Robbins et al. Page 28














Dose-dependent reductions in regional SPECT perfusion and ventilation, as well as
increases in CT density in patients receiving lung irradiation. [Adapted from Marks (114)
with permission; data from Netherlands Cancer Institute (109, 111, 112) and Duke (100,
113).]
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Cardiac SPECT scans showing representative axial images obtained (panel A) pre-RT and
(panel B) post-RT. The deep tangent border is shown as the solid line. A new perfusion
defect after irradiation is seen in the anterior left ventricle. [Adapted from Marks et al. (134)
with permission.]
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TABLE 2
Compared Frequencies of Radiographic and Symptomatic Cardiac Changes after Thoracic Irradiation
[Adapted from Hubbs (126) with permission]





Breast cancer – retrospective
 Gyenes, 1994 (140) 1971–1976 37 18.4 years Left-sided photons or electrons 25% (5/20)
19 years Right-sided photons or electrons 0% (0/17)
 Gustavsson, 1999 (141) 1978–1983 90 13 years Left-sided RT 12% (4/34)
Right-sided or no RT 4% (2/56)
 Højris, 2000 (142) 1982–1990 16 7.9 years Left-sided electrons 44% (4/9)
No RT 57% (4/7)
 Cowen, 1998 (143) 1987–1993 17 8.4 years Left-sided photons 0% (0/17)
 Girinsky, 2000 (144) 1987–1995 36 6.7 years Left-sided photons 71% (17/24)
8.3 years Right-sided photons 17% (2/12)
Breast cancer – prospective
 Gyenes, 1996 (136) 1993–1994 12 1.1 year Left-sided photons 100% (4/4)
Left-sided electrons 25% (2/8)
 Marks, 2005 (134) 1998–2001 114 0.5 year Left-sided photons 27% (21/77)
1 year Left-sided photons 29% (16/55)
1.5 years Left-sided photons 38% (13/34)
2 years Left-sided photons 42% (11/26)
 Prosnitz, 2007 (135) 1998–2006 44 3 years Left-sided photons 38% (3/8)
4 years Left-sided photons 58% (7/12)
5 years Left-sided photons 67% (4/6)
6 years Left-sided photons 67% (2/3)
Other disease sites
 Savage, 1990 (145) 1967–1985 16 9.3 (2.5–21.5) years Hodgkin’s disease 0% (0/16)
 Gustavsson, 1990 (146) 26 15 (4–20) years Hodgkin’s disease 61% (14/23)
 Maunoury, 1992 (147) 1978–1988 31 7 (3–11) years Hodgkin’s disease 84% (21/25)
 Glanzmann, 1998 (148) 1964–1992 112 11.2 (1.0–31.5) years Hodgkin’s disease 7% (7/100)
 Girinsky, 2000 (144) 49 75 (28–208) months Hodgkin’s disease 78% (32/41)
 Heidenreich, 2007 (149) 1964–1994 294 6.5 (4.0–8.4) years Hodgkin’s disease 12% (32/274)
 Gayed, 2006 (150) 2005–2006 51 3 months Esophageal cancer 54% (14/26)
 Lind, 2006 (151) 13 2 months, 6 months Lung cancer
 Hubbs, 2008 (152) 2006–2007 12 3, 6, 12, and 18 months Lung cancer, Mesothelioma 50% (6/12)
Radiat Res. Author manuscript; available in PMC 2013 August 05.
